Pfizer has said that its experimental Covid-19 pill appears effective against the Omicron variant, reports AP.
The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the virus: The drug reduced combined hospitalisations and deaths by about 89 per cent among high-risk adults when taken shortly after initial Covid-19 symptoms.
Separate laboratory testing shows the drug retains its potency against the Omicron variant, the company announced, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that Omicron uses to reproduce itself.
